SUMMARY

Immunotherapy currently holds the most potential for cancer treatment, with T-cell therapies as one promising approach. The team develops a high throughput platform to identify T cell receptors (TCRs) specific for cancer antigens for a novel and effective T-cell therapy for untreatable blood cancer patients. Preliminary studies not only demonstrated the feasibility of the strategy, but also identified two novel TCRs. Patents covering these TCRs as well as the platform have been filed. The team is setting up a startup (called Captain T Cell) and has acquired follow-on funding to further pursue the strategy. They aim for testing their TCR therapy in a clinical phase I/IIa study and also hope to develop T-cell immunotherapies for other tumor-related illnesses in the foreseeable future.

PROJECT ACHIEVEMENTS DURING & AFTER SPARK

- Robust platform established to develop >30 isolated TCRs
- Multiple patents filed from 2015-2020
- Winner at life sciences and healthcare startup accelerator OneStart in 2016
- Jury price at BioVaria showcasing event for life science technologies in 2017
- GO-Bio Funding in 2018
- Total follow-on pre-seed funding of 4 Mio. € until 2020
- Startup planned for 2021/22